Lycera Stock

lycera.comHealthcare / BioTech & PharmaFounded: 1900Funding to Date: $106.06MM

Lycera is a biopharmaceutical company that seeks to uncover new small molecule therapies for the treatment of autoimmune diseases and cancer.

Register To Buy and Sell Shares

For more details on financing and valuation for Lycera, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Lycera’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Lycera.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Alex Howarth
Chief Financial Officer
William Sibold
Co-Chief Executive Officer & President
Bruce Goldsmith Ph.D
Chief Operating Officer and Chief Business Officer
Paul Sekhri
President, Co-Chief Executive Officer & Board Member
H. Jeffrey Wilkins MD
Chief Medical Officer

Board Members

Jeffrey Leiden Ph.D
Blackstone Life Sciences
Michael Hayden Ph.D
Pablo Cagnoni MD
Robert Kamen Ph.D
Mary Campbell
EDF Ventures
Nina Kjellson
InterWest Partners
Paul Sekhri
Steven Gillis Ph.D
ARCH Venture Partners
Kristina Burow
ARCH Venture Partners
Nicholas Simon
Blackstone Life Sciences
Finny Kuruvilla Ph.D
Blackstone Life Sciences
Timothy Mayleben
Updated on: Dec 2, 2023


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.